SINT — Sintx Technologies, Inc.

Amedica Corporation Q3 2017 Earnings Call Summary

1. Key Financial Results and Metrics:

   • Total revenue for Q3 2017 was $3 million, a decrease of $0.4 million from Q3 2016.
   • Silicon nitride ceramic products accounted for 41% of product sales, decreasing by $0.7 million year-over-year.
   • Metal sales represented 59% of product sales, increasing by $0.2 million compared to the prior year.
   • Net loss narrowed to $2.8 million from $4.3 million in the same quarter last year, attributed to reduced operating expenses from a restructuring effort.
   • Cash balance stood at $2.8 million as of September 30, 2017.
   • Operating cash burn decreased to $4.4 million for the nine months ended September 30, 2017, down from $5.3 million in 2016.

2. Strategic Updates and Business Highlights:

   • Amedica focused on stabilizing spine sales, increasing surgeon users by 30% and sales agents by 15%.
   • Successful launch of the Taurus Pedicle Screw System, generating over $1 million in revenue from over 200 surgeries performed.
   • Ongoing multi-center retrospective clinical study to assess the effectiveness of silicon nitride spinal implants.
   • Continued investment in R&D, resulting in 19 peer-reviewed journal articles and multiple collaborations with academic institutions.
   • Amedica filed a 510(k) submission for its Valeo C+CSC with Lumen spinal implant, aiming to introduce proprietary technology to the U.S. market.
   • Reduced total debt to approximately $4.6 million, down from $7 million in December 2016.

3. Forward Guidance and Outlook:

   • Amedica aims to continue growing sales, particularly in the U.S. market, while exploring international opportunities.
   • The company expects the release of additional instrument sets for the Taurus System to drive revenue growth.
   • Anticipation of FDA response regarding the 510(k) submission, which could enhance product offerings.

4. Bad News, Challenges, or Points of Concern:

   • Revenue decline in silicon nitride products due to loss of surgeons and the impact of previous restructuring efforts.
   • Price erosion contributed to decreased revenue, indicating potential competitive pressures.
   • The company faces ongoing challenges in regaining market share lost during the restructuring phase.

5. Notable Q&A Insights:

   • The call did not include a formal Q&A session; however, the CEO encouraged stakeholders to send questions and suggestions via email for future engagement.

Overall, Amedica is making strides in stabilizing its business and reducing debt, but faces challenges in revenue generation and market competition. The focus remains on growth through new product launches and ongoing research initiatives.